drugset / Trial / NCT02087085

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085

Phase 2 Terminated 310 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.

Timeline

Start
2014-05-09
Primary completion
2018-03-30
Completion
2018-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 400 ug Intravitreal